摘要
Radiopharmaceuticals have gained significant traction since 2016, following mul-tiple U.S. Food and Drug Administration (FDA) approvals for the detection, monitoring, and treatment of a multitude of diseases. The general metal-based radiopharmaceutical scaffold consists of a targeting motif that binds to a biological target with high affinity and specificity, conjugated to a chelator-radiometal complex by a linker molecule for the transport of a diagnostic or therapeutic radioisotope. The high specificity of the targeting molecule allows for preferential accumulation of the radiotracer at the intended site while minimizing radiation exposure to healthy tissues. However, many peptide-based radiotrac-ers exhibit rapid systemic clearance, which can reduce the radiopharmaceuticals' therapeu-tic efficacy toward the target. One strategy to enhance tumor accumulation, reduce off-target uptake, and extend the biological half-life of a radiotracer involves conjugating a small-molecule albumin-binding moiety (ABM) to the radiopharmaceutical scaffold. De-spite these advantages, careful optimization is required to balance improved tumor uptake with prolonged blood retention to achieve optimal therapeutic performance. I aimed to evaluate the performance of various albumin binders (AB) using in vitro biophysical assays and in vivo targeting studies in a metastatic melanoma model. The most abundant serum protein, albumin, serves as a natural transporter for a wide range of endog-enous and exogenous compounds throughout the circulatory system. In the pharmaceutical industry, albumin has been leveraged as a drug carrier to enhance systemic circulation, protect pharmaceutical agents from enzymatic degradation, and increase the bioavailability at target sites. I investigated a series of ABMs, including the established gold standard p- iodophenyl butyric acid (pIBA) and the fluorescent dansylated amino acid, dansyl-L-phe-nylalanine (DanF). With amino acid residue differences occurring between both human and murine albumin, ABMs with and without adjacent acetyl-lysine linkers were evaluated for binding affinity using fluorimetry. Biophysical analyses revealed that certain ABMs without acetyl-lysine had preferential binding to one albumin species over the other (hu-man vs murine serum albumin), and that the coupling of an adjacent linker, designed to mimic the structural context of a complete radiotracer, influenced albumin-binding affinity. The ABMs were subsequently conjugated to a variety of radiotracer scaffolds incorporat-ing distinct chelators that coordinate 89Zr4+ and 177Lu3+, which were then administered to mice bearing subcutaneous B16F10 tumors in a metastatic melanoma model. The radio-pharmaceutical scaffold incorporating pIBA demonstrated the greatest promise by signifi-cantly increasing tumor uptake and retention; however, its prolonged blood circulation prompted further investigation into weaker albumin-binding moieties. In contrast, Phe-noxy, Bromo phenoxy, and DanF did not produce an overall improvement in the pharma-cokinetic profiles of the evaluated radiotracers. Notably, preferential albumin species–de-pendent binding was observed through both computational modeling and fluorimetric anal-yses, highlighting the importance of optimizing the structures of small albumin-binding molecules to favorably modulate pharmacokinetics and enable effective translation to the clinical setting.